ReviewProteomics. Clinical applications2016
Recombinant antibodies for diagnostics and therapy against pathogens and toxins generated by phage display.
Review in Proteomics. Clinical applications, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 82 citations in OpenAlex.
- Discovery of Landscape Phage Probes Against Cellular Communication Network Factor 1 (CCN1/Cyr61).Viruses · 2025Article
- Development of novel neutralizing single-chain fragment variable antibodies against S100A8.Scientific reports · 2025Article
- Article
- rAbDesFlow: a novel workflow for computational recombinant antibody design for healthcare engineering.Antibody therapeutics · 2024Article
- Phage Display Technology in Biomarker Identification with Emphasis on Non-Cancerous Diseases.Molecules (Basel, Switzerland) · 2024Review
- Genetically engineered bacteriophages as novel nanomaterials: applications beyond antimicrobial agents.Frontiers in bioengineering and biotechnology · 2024Review
- A fine-tuned yeast surface-display/secretion platform enables the rapid discovery of neutralizing antibodies against Clostridioides difficile toxins.Microbial cell factories · 2023Article
- Article
- Phage display technology for fabricating a recombinant monoclonal ScFv antibody against tetanus toxin.Toxicology research · 2023Article
- Production of recombinant scorpion antivenoms in E. coli: current state and perspectives.Applied microbiology and biotechnology · 2023Review
- Antibody Phage Display Technology for Sensor-Based Virus Detection: Current Status and Future Prospects.Biosensors · 2023Review
- Targeting the Inside of Cells with Biologicals: Toxin Routes in a Therapeutic Context.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2023Review
- Antibody Selection via Phage Display in Microtiter Plates.Methods in molecular biology (Clifton, N.J.) · 2023Review
- Antibody Selection in Solution Using Magnetic Beads.Methods in molecular biology (Clifton, N.J.) · 2023Article
- Mapping Epitopes by Phage Display.Methods in molecular biology (Clifton, N.J.) · 2023Article
- Advances in phage display based nano immunosensors for cholera toxin.Frontiers in immunology · 2023Review
- A SARS-CoV-2 neutralizing antibody discovery by single cell sequencing and molecular modeling.Journal of biomedical research · 2022Article
- Expression of mammalian proteins for diagnostics and therapeutics: a review.Molecular biology reports · 2022Review
- Rapid-format recombinant antibody-based methods for the diagnosis ofFrontiers in microbiology · 2022Review
- Recombinant antibodies and their use for food immunoanalysis.Analytical and bioanalytical chemistry · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibodies are valuable molecules for the diagnostic and treatment of diseases caused by pathogens and toxins. Traditionally, these antibodies are generated by hybridoma technology. An alternative to hybridoma technology is the use of antibody phage display to generate recombinant antibodies. This in vitro technology circumvents the limitations of the immune system and allows-in theory-the generation of antibodies against all conceivable molecules. Phage display technology enables obtaining human antibodies from naïve antibody gene libraries when either patients are not available or immunization is not ethically feasible. On the other hand, if patients or immunized/infected animals are available, it is common to construct immune phage display libraries to select in vivo affinity-matured antibodies. Because the phage packaged DNA sequence encoding the antibodies is directly available, the antibodies can be smoothly engineered according to the requirements of the final application. In this review, an overview of phage display derived recombinant antibodies against bacterial, viral, and eukaryotic pathogens as well as toxins for diagnostics and therapy is given.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.